Mental or Behavioral Dysfunction – Page 6

LinusBio Introduces ClearStrand-ASD: Revolutionary Autism Diagnostic Aid Using Hair Analysis

12 months ago talkbio0Tagged Autistic Disorder, biomarker test, ClearStrand-ASD, Detection, Diagnosis, Exposome, Hair Analysis, LinusBio, Negative Predictive Value of Diagnostic Test

LinusBio, ClearStrand-ASD, autism diagnostic, hair analysis, biomarker test, early detection, negative predictive value, exposome medicine

Congressional Healthcare Reform Priorities Under Trump’s Second Term

12 months ago talkbio0Tagged Alcohol abuse, Medicaid block grants, Medicare, Prices, repeal, Value-Based Care

ACA repeal, Medicaid block grants, price transparency, Medicare Advantage, drug pricing, value-based care

RFK Jr. Dodges Vaccine-Autism Questions in Senate Confirmation Responses

12 months ago talkbio0Tagged Autistic Disorder, CHARGE Syndrome, Confirmation, Hearings, Misinformation, Response process, Robert F. Kennedy, Secretary Nomination, Senate, Vaccines, Written - Consent Mode

Robert F. Kennedy Jr., HHS Secretary nomination, vaccine misinformation, autism, Senate confirmation hearings, written responses

FDA Approves Monthly Maintenance Dosing for Eisai and Biogen’s Alzheimer’s Drug Leqembi

12 months ago talkbio0Tagged Alzheimer 's disease, amyloid-beta, Approved, Biogen, dosing, Eisai, Leqembi, Maintenance, Mental deterioration, monthly, United States Food and Drug Administration

Leqembi, Alzheimer’s disease, FDA approval, monthly maintenance dosing, Eisai, Biogen, amyloid-beta, cognitive decline

Sage Therapeutics Rejects Biogen’s Acquisition Bid, Initiates Strategic Review

12 months ago talkbio0Tagged Acquisition, Biogen, Depression, Postpartum, Drug Industry, M&A, strategic alternatives, Zurzuvae

Sage Therapeutics, Biogen, acquisition rejection, strategic alternatives, ZURZUVAE, postpartum depression, pharmaceutical industry, M&A

Sage Therapeutics Rejects Biogen’s Acquisition Proposal, Remains Open to Future Deals

12 months ago talkbio0Tagged Acquisition, Biogen, Depression, Postpartum, Neurodevelopmental Disorders, Neuropsychiatry, proposal - intent, Zurzuvae

Sage Therapeutics, Biogen, Acquisition Proposal, Postpartum Depression, ZURZUVAE, Neurodevelopmental Disorders, Neuropsychiatry

Johnson & Johnson’s Darzalex and Spravato Achieve Milestones: Darzalex Leads Sales, Spravato Surpasses $1 Billion Revenue

1 year ago talkbio0Tagged Darzalex, Johnson and Johnson, Mental Depression, Multiple Myeloma, Pharmaceutical Sales, Revenue Milestones, Spravato

Johnson & Johnson, Darzalex, Spravato, Pharmaceutical Sales, Multiple Myeloma, Depression Treatment, Revenue Milestones

J&J’s Spravato Surpasses $1 Billion in Revenue for 2024

1 year ago talkbio0Tagged 2024, J&J, Mental Depression, Nasal Spray, Spravato

J&J, Spravato, revenue, 2024, depression treatment, nasal spray

Boehringer Ingelheim’s Iclepertin Fails to Meet Primary and Secondary Endpoints in Phase III Schizophrenia Trials

1 year ago talkbio0Tagged Boehringer Ingelheim, CONNEX, Iclepertin, Impaired cognition, Phase 3 Clinical Trials, Programs - Publication Format, Schizophrenia

Boehringer Ingelheim, iclepertin, schizophrenia, Phase III trials, cognitive impairment, CONNEX program

Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion, Bolstering Neuroscience Portfolio

1 year ago talkbio0Tagged Acquisition, Caplyta, Depression, Bipolar, Intra-Cellular Therapies, Johnson and Johnson, Lumateperone, Neuroscience discipline, Schizophrenia

Johnson & Johnson, Intra-Cellular Therapies, Acquisition, Neuroscience, CAPLYTA, Lumateperone, Bipolar Depression, Schizophrenia, Major Depressive Disorder